Navigation Links
IVCC and Syngenta reach key insecticide development milestone
Date:4/23/2010

The Innovative Vector Control Consortium (IVCC) and Syngenta announced today that the latest field trials of the new Actellic 300CS micro-encapsulated formulation demonstrate effective control of pyrethroid resistant mosquitoes on treated construction materials for more than eight months.

Developed by Syngenta, and tested in laboratory and field evaluations by Syngenta and IVCC partner laboratories in Switzerland and Africa, Actellic 300CS has subsequently been submitted to the World Health Organization Pesticide Evaluation Scheme (WHOPES) for independent performance and safety assessment. A recommendation from the WHO at the end of the evaluation process is a key requirement for many aid funded malaria control programs.

"The field data for Actellic 300CS has surpassed our original expectations and shows real promise as a valuable tool to complement our existing products," said Mark Birchmore, Syngenta's Global Brand Manager for Vector Control. "Working together with the IVCC enables us to leverage our expertise and capabilities to develop new products that meet the needs of current and future malaria control programs."

Actellic 300CS is the result of applying advanced micro-encapsulation technology to the WHO recommended insecticide, pirimiphos-methyl, to develop a new long lasting product which targets malaria mosquitoes resistant to the pyrethroid class of insecticides. Current alternatives to pyrethroids typically only last for 3 months after application resulting in additional cost and complexity for malaria programs. The submission to WHOPES is a major step forward in making the product available to national malaria control programs.

Dr Tom McLean, IVCC's Chief Operating Officer, said: "The more effective control of mosquitoes is vital to the fight against malaria. Current tools can be highly effective but resistance threatens the effectiveness of existing products. We need innovative solutions to sustain the ground gained over malaria in recent years and to continue the push towards eventual eradication.

"This project amply demonstrates that IVCC's concept of covering initial risk to stimulate innovation is working and that industry has enthusiastically bought into the product development partnership model which we have pioneered for vector control."

Syngenta and the IVCC have been collaborating on projects to develop novel products for improved vector control since 2007. A second key project includes leveraging Syngenta's vast compound collection and research expertise to specifically search for new insecticides for adult mosquito control. Early results are very encouraging with a number of separate chemical classes showing promise for further development.


'/>"/>

Contact: Alan Hughes
a.p.hughes@liv.ac.uk
Liverpool School of Tropical Medicine
Source:Eurekalert

Related biology news :

1. IVCC and Syngenta start project for novel insecticidal active ingredient for malaria control
2. Syngenta Crop Protection Canada announces seed treatment project with Innovotech
3. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
4. Rutgers high school outreach gets $3 million boost from NSF
5. Cogent Systems and Northrop Grumman Reach Agreement to Settle Automated Fingerprint Identification Technology Suit and Create Strategic Alliance
6. Thinking makes it so: Science extends reach of prosthetic arms
7. Carnivores in recent study help Bergmanns rule reach the 21st century
8. Private Rocketeers reach for space -- science writer in Canada to explain
9. Undergraduate bioscience research reaches new horizons
10. APS names 2 minority outreach fellows
11. PNNL reaches goal to change world one light at a time
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2016)... 2016 WearablesResearch.com , a brand of ... results from the Q1 wave of its quarterly wearables ... consumers, receptivity to a program where they would receive ... insurance company. "We were surprised to see ... Michael LaColla , CEO of Troubadour Research, "primarily because ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... , June 27, 2016  Liquid Biotech ... the funding of a Sponsored Research Agreement with ... tumor cells (CTCs) from cancer patients.  The funding ... CTC levels correlate with clinical outcomes in cancer ... data will then be employed to support the ...
(Date:6/24/2016)... June 24, 2016 Epic Sciences unveiled ... cancers susceptible to PARP inhibitors by targeting homologous ... (CTCs). The new test has already been incorporated ... multiple cancer types. Over 230 clinical ... response pathways, including PARP, ATM, ATR, DNA-PK and ...
(Date:6/23/2016)... ... 23, 2016 , ... Mosio, a leader in clinical research ... Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits the ... tools, and strategies for clinical researchers. , “The landscape of how patients receive ...
(Date:6/23/2016)... 23, 2016 /PRNewswire/ - FACIT has announced the ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or ... of a portfolio of first-in-class WDR5 inhibitors for ... as WDR5 represent an exciting class of therapies, ... medicine for cancer patients. Substantial advances have been ...
Breaking Biology Technology: